TREATMENT
Phase II trial tests anti-EGFR rechallenge in ctDNA-selected metastatic CRCThe ROMANCE trial is randomizing 150 patients with circulating tumor DNA-negative hyperselected metastatic colorectal cancer to irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab as third-line therapy, aiming to improve objective response rates. (Clinical Colorectal Cancer)